Skip to main content
. 2016 Dec 16;11:44. doi: 10.1186/s40248-016-0080-1

Table 2.

Clinical data after 12 ± 2 months of optimized therapy

Overall cohort Group A
FEV1 ≥ 80%
Group B
FEV1 < 80 ≥ 60%
Group C
FEV1 < 60%
n 817 508 202 107
FEV1% 93.79 (±0.70) 103.92 (±0.60) 83.92 (±1.00) 64.34 (±1.73)
Relapses, n,a 0.45 (±0.03) 0.31 (±0.03) 0.62 (±0.08) 0.79 (±0.12)

Mean (±SE, standard error)

FEV1%: forced expiratory volume in 1 s, predicted values

aRelapses with and without hospitalization